Use of a preference-based measure of health (EQ-5D) in COPD and asthma  by Simon Pickard, A. et al.
ARTICLE IN PRESS
Respiratory Medicine (2008) 102, 519–5360954-6111/$ - see fro
doi:10.1016/j.rmed.
Abbreviations: CO
obstructive lung dis
volume 1 s; AQLQ, As
asthma; UK, United
Corresponding au
of Pharmacy, Room 1
fax: +1 312 996 0397.
E-mail address: pUse of a preference-based measure of health (EQ-5D)
in COPD and asthma
A. Simon Pickarda,b,, Caitlyn Wilkea, Eunmi Junga, Sneh Patela,
Knut Stavemc, Todd A. Leeb,daCenter for Pharmacoeconomic Research, Departments of Pharmacy Practice and Pharmacy Administration,
College of Pharmacy, Room 164, 833 South Wood Street (MC886), University of Illinois at Chicago, Chicago, IL 60612, USA
bCenter for Management of Complex Chronic Disease, Hines VA Hospital, Hines, IL 60141, USA
cMedical Department, Akershus University Hospital, Lørenskog NO-1478, Norway
dNorthwestern University, Feinberg School of Medicine, Chicago, IL 60611, USA
Received 24 July 2007; accepted 27 November 2007
Available online 3 January 2008KEYWORDS
Asthma;
COPD;
Health outcomes;
Quality of life;
EQ-5Dnt matter & 2007
2007.11.016
PD, chronic obstru
ease; SD, standar
thma Quality of Li
Kingdom; SE, stan
thor. Center for P
64, 833 South Wo
ickard1@uic.eduSummary
Background: EQ-5D is a generic preference-based measure of health that can help to
understand the impact of asthma and chronic obstructive pulmonary disease (COPD). The
purpose of this paper was to synthesize literature on the validity and reliability of EQ-5D
use in studies of asthma and COPD, and estimate EQ-5D utility scores associated with stage
of disease.
Methods: A structured search was conducted in EMBASE and MEDLINE (1988–2007) using
keywords relevant to respiratory disease and EQ-5D. Original research studies in asthma or
COPD that reported EQ-5D results and/or psychometric properties were included.
Results: Studies that reported psychometric properties supported the construct validity,
test–retest reliability, and responsiveness of EQ-5D in asthma (seven studies) and COPD
(nine studies), although some evidence of ceiling effects were observed in asthma studies.
In asthma studies that reported summary scores (n ¼ 11), EQ-5D index-based scores ranged
from 0.42 (SD 0.30) to 0.93 (SD not reported). In COPD studies (n ¼ 8), scores ranged from
0.52 (SD 0.16) to 0.84 (SD 0.15). While few asthma studies reported scores by severity
level, sufficient studies in COPD were available to calculate pooled mean utility scores
according to GOLD stage: stage I ¼ 0.74 (0.62–0.87), stage II ¼ 0.74 (0.66–0.83), stage
III ¼ 0.69 (0.60–0.78) and stage IV ¼ 0.61 (0.44–0.77) (most severe).Elsevier Ltd. All rights reserved.
ctive pulmonary disease; HRQL, health related quality of life; GOLD, the global initiative for chronic
d deviation; VAS, visual analog scale; DALYs, disability adjusted life years; FEV1, forced expiratory
fe Questionnaire; SF-36, Short Form-36; QALY, quality adjusted life years; GINA, the global initiative for
dard error; NASQ, Newcastle Asthma Symptoms Questionnaire.
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A. Simon Pickard et al.520Conclusions: Evidence generally supported the validity and reliability of EQ-5D in asthma
and COPD. Utility scores associated with COPD stage may be useful for modeling health
outcomes in economic evaluations of treatments for COPD.
& 2007 Elsevier Ltd. All rights reserved.Introduction
Chronic respiratory diseases including asthma and chronic
obstructive pulmonary disease (COPD) impose a tremendous
burden on societies around the world. Chronic respiratory
illnesses account for 7% of deaths worldwide.1 Globally,
asthma affects 300 million people.2 The prevalence and
burden of COPD is predicted to increase in the coming
decades and is expected to be the third leading cause of
mortality in the world by 2020.3 Because asthma and COPD
are chronic conditions, patient management focuses on the
alleviation of symptoms that can adversely affect health
status and quality of life.Articles Identified by  
LINE and EMBASE Search 
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Figure 1 Summary ofIn clinical practice, physiological factors such as forced
expiratory volume in 1 s (FEV1) have been used to assess
severity of asthma and COPD. Although physiological
markers are one approach to evaluate the effect of disease,
such clinical measures are limited in the information they
provide about patient health.4 To understand and evaluate
how asthma and COPD patients feel about their health,
disease-specific and generic measures of health are often
used. Examples of disease specific measures include the
Asthma Quality of Life Questionnaire (AQLQ) for asthma5
and the St. George’s Respiratory Questionnaire,6 while the
Short Form-36 (SF-36)7,8 and EQ-5D are generic measures of
health used in both asthma and COPD.Articles Identified on Euroqol 
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Table 1 Characteristics of asthma and COPD studies using EQ-5D.
Author, year, reference
number
Study design Treatment information Demographic
group
M/F (%) Mean (SD) Age
[Range]
Asthma
Burstrom, et al.
(2001)19
Prospective,
cross-
sectional
N/R No asthma-specific demographics reported.
See original paper for population-level
demographics
Garratt, et al. (2000)20 Prospective,
longitudinal
N/R All (asthma) N/R
Lubetkin et al. (2005)21 Retrospective,
cross-
sectionaly
N/R All
(population)
43/57 See original
article for
stratified ages
Oga et al. (2003)22 Prospective,
cross-
sectional
Stepwise use of short acting
bronchodilator, low dose
inhaled glucocorticosteroids,
regular bronchodilators, and
regular oral prednisolone
All (asthma) 41/59 46.8 (19.3)
[19–87]
Szende et al. (2004)23 Prospective,
cross-sectional
,z
N/R All (asthma) 34/66 49.0
Wasserfallen et al.
(1999)24
Prospective,
longitudinal
Inhaled bronchodilators
(61.9%); Inhaled
corticosteroids (52.4%);
Theopylline (14.3%); Oral
bronchodilators (23.8%); Oral
corticosteroids (9.5%);
Ipratropium (14.3%); Table 1
of original document.
Asthma and
Allergic
rhinitis
24/76 44.6
[29–66]
COPD
Brazier et al. (2004)25 Secondary data analysis. See details for Harper (1997)27
Covelli et al. (2005)26 Prospective,
longitudinaly
Oxygen therapy (3.6%), Short
acting b2 agonist (74.5%);
Long acting b2 agonist
(51.0%); Anticholinergics
(61.2%); Theophylline (5.6%);
Inhaled glucocorticosteroids
(56.1%)
All (COPD) 58/42 64.6 (9.1)
Harper et al. (1997)27 Prospective,
longitudinal
Oxygen therapy (15%);
‘‘practically all patients used
inhalers’’
COPD 49/51 M: 67 (10.4)
F: 62 (10.3)
Punekar et al. (2007)38 Prospective,
cross-
sectionaly
N/R PCP 66/34 66.0 (0.3)
RS 71/29 66.0 (0.3)
Rutten-Van Molken et
al. (2006)28
Retrospective,
longitudinalz
5% (n ¼ 67) using oxygen
therapy at home;
ipratroprium bromide;
salbutamol
All (COPD) 73/27 64.5 (8.4)
GOLD II 71/29 64.0 (8.4)
GOLD III 75/25 65.6 (8.2)
GOLD IV 76/24 61.6 (8.4)
Stahl et al. (2005)44 Retrospective,
cross-
sectionalz
N/R All (COPD) 64.3
[28–80]
Stavem (1999)30 Prospective,
longitudinal
N/R All (COPD) 57/43 57.0 (9.1)
Stavem and Jodalen
(2002)31
Prospective,
cross-
sectionalz
N/R All (COPD) 58/42 57.4 (9.0)
EQ-5D use in COPD and asthma 521
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Table 1 (continued )
Author, year, reference
number
Study design Treatment information Demographic
group
M/F (%) Mean (SD) Age
[Range]
Hazell et al. (2003)32 Prospective,
cross-
sectionaly
N/R ALL
(population)
55/45 45.8 (19.4)
[16–99]
Savoia et al. (2006)33 Prospective,
cross-
sectional
N/R All (Italian
population)
48/52 50.2 (18.1)
[18–93]
Sullivan et al. (2005)37 Retrospective,
cross-
sectionalz
N/R COPD 51.0
Asthma 46.0
See Appendix A for abbreviations.
Compare HRQL measures.
yDescription of patient population.
zComparison of multiple conditions or stages of illness.
yClinical comparison of treatments or procedures.
zHRQL instrument development.
Table 2 Psychometric properties of the EQ-5D in asthma and COPD.
Author, year, reference Validity Reliability/responsiveness
Asthma
Badia et al. (2001)34 Convergent—Fisher’s exact test of association
between EQ-5D domains and PAQLQ dimensions.
Highest relationships between EQ-5D PD and PAQLQ
symptoms; EQ-5D UA with PAQLQ limitation of
activities; EQ-5D AD with PAQLQ emotional functioning
Burstrom et al. (2001)19 Predictive—Multiple regression predicting EQ-5D.
Asthma was a marginally significant predictor in the
model (p ¼ 0.0604, p ¼ 0.0392 when controlling for
socio- economic group)
Garratt et al. (2000)20 Convergent—Pearson’s correlation with EQ-5D index.
High correlation with AQLQ Activity; moderate
correlation with NASQ, AQLQ overall, AQLQ symptoms,
AQLQ emotion, SF-12 PCS; low correlation with AQLQ
Environment, SF-12 MCS
Responsiveness—SRM, baseline to
6 months for the EQ-5D index.
Significant linear relationship
between change scores and self-
reported asthma transition
(SRM ¼ 0.29)
Construct—Known groups comparisons of EQ-5D index
scores using independent samples t-tests. All tests
were in the direction hypothesized, significant for
post-school education (t ¼ 4.52), but nonsignificant
for smoking (t ¼ 0.85) and degree (t ¼ 1.78)
Lubetkin et al. (2005)21 Predictive—Regression predicting EQ-5D index and EQ-
5D VAS. Asthma was significant predictor of EQ-5D
index and VAS, after controlling for age, sex, race/
ethnicity, condition (po0.0001)
Oga et al. (2003)22 Convergent—Changes in EQ-5D index significantly
correlated with changes in total symptoms, activities,
and emotions of AQLQ (no statistic given)
Responsiveness—Effect Size and
SRM, baseline to 3 and 6 months.
Small to medium responsiveness of
EQ-5D index from 0 to 3 months
(ES ¼ 0.41; SRM ¼ 0.36) and 0–6
months (ES ¼ 0.36; SRM ¼ 0.32)
A. Simon Pickard et al.522
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Table 2 (continued )
Author, year, reference Validity Reliability/responsiveness
Szende et al. (2004)23 Convergent—Pearson’s correlation. High correlation
with SF-36 PCS, SGRQ; moderate correlation with MCS,
TTO; low correlation with FEV1
Discriminant—Ceiling/floor effects of EQ-5D index and
SF-6D. EQ-5D index shows ceiling effects, is limited in
measuring very mild asthma; EQ-5D index better
discriminates that SF-6D for patients with poor disease
control
Wasserfallen et al.
(1999)24
Construct—Spearman correlations. High correlation of
EQ-5D VAS with asthma symptom and bother scores,
and Rhinoconjunctivitis Quality of Life Questionnaire
Responsiveness—Mean differences
using Wilcoxon paired rank tests.
Significant difference in VAS scores
between minimum and maximum
evaluations by the MAQOL
(p ¼ 0.005) but less responsive
than symptom scale, bother scale,
and disease specific
Rhinoconjunctivitis Quality of Life
Questionnaire.
COPD
Brazier et al. (2004)25 Convergent—EQ-5D index compared to SF-6D;
ICC ¼ 0.28; R2 ¼ 0.19; these were the lowest
correlations of all 7 datasets
Covelli et al. (2005)26 Construct—Known groups comparisons of tiotropium
to control; Fewer problems in tiotropium group for
self-care domain only; significantly higher VAS scores
for tiotropium group (po0.01)
Harper et al. (1997)27 Construct—Known groups comparisons of COPD
patients with age and sex matched general population
controls from the same city. EQ-5D scores of COPD
patients indicated poorer health (no statistic reported)
SRM between initial and first and
second follow-up. Significant mean
difference using the EQ-5D VAS
(po0.001) but insignificant using
the EQ-5D (p ¼ 0.28).
Construct—Known groups comparisons using effect
size. Breathless detection tests found large ES using
EQ-5D Index and VAS (ESZ1.0); 6 min walking test
discrimination using the EQ-5D index and VAS was
moderate; Self-reported breathless scores (using a
VAS) at the end of 6 min walking test found moderate
ES using EQ-5D index and VAS. FEV1 predicted has
small ES using index and VAS scores. See original paper
for cutoff values between ES groups
Test-retest reliability—Mean
differences and ICC of unchanging
patients from baseline to 6
months. EQ-5D index and VAS
showed non-significant mean
differences and moderate ICCs
(index mean difference ¼ 0.8,
ICC ¼ 0.67; VAS mean
difference ¼ 0.2, ICC ¼ 0.67)
Rutten-Van Molken et al.
(2006)28
Construct—ANCOVA adjusted for age, gender, smoking
status, pack-years of smoking, BMI, and number of
comorbidities. EQ-VAS, EQ-5D index (US and UK
algorithms) are all able to detect significant
differences between GOLD stages (po0.001)
Construct—Known groups comparison of
discrimination between GOLD stages using effect size.
EQ-5D index (US and UK algorithms) differentiate
between GOLD II and III (ES ¼ 0.22 for US, 0.18 for UK)
better than GOLD III and IV (ES ¼ 0.47 for both). EQ-5D
VAS differentiates between GOLD III and IV (ES ¼ 0.27)
better than GOLD II and III (ES ¼ 0.32)
Predictive (Criterion)—Regression predicting EQ-5D in
an asthma patient population. Gender, Post-
bronchodilator therapy FEV %, No. of ER visits, No. of
hospital admissions, No of CDs, and BMI significant in
model (all po0.035)
EQ-5D use in COPD and asthma 523
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Table 2 (continued )
Author, year, reference Validity Reliability/responsiveness
Stahl et al. (2005)29 Convergent—Pearson’s correlations. EQ-5D VAS: high
correlation with PCS, SGRQ and EQ-5D index;
moderate with MCS. EQ-5D index: high correlation with
PCS, EQ-VAS, SGRQ; moderate with MCS
Stavem (1999)30 Convergent—Spearman’s correlations. Moderate
correlations with SF-36 PCS and MCS; low correlation
with Karnofsky
Test–retest—2 week separation
using Spearman rank correlations.
High correlation (r ¼ 0.7)
between time points.
Convergent—Mean differences between scoring types.
Significant difference in mean compared to a 15D
version; No significant differences between EQ-5D and
SG and TTO exercises
Effect size—Medium ES for COPD
patients whose global rating
improved (ES ¼ 0.55) but low for
those with worse global rating of
change (ES ¼ 0.07)
Construct—Spearman’s correlations with functional
measures. Moderate correlation with oxygen use; Low
correlation with 6 minute walk, PaO2; No correlation
with dysphoea, end exercise, FEV
Responsiveness statistic—Larger
statistic for COPD patients with
better global change in health
status over 12 months ( ¼ 1.18)
as compared to worse global
change ( ¼ 0.14)
Stavem and Jodalen
(2002)31
Convergent—Pearson correlations between EQ-5D
(MO, SC, UA, PD, AD) items and COOP/ WONCA Physical
functioning (PF), Daily Activities (DA) and Feelings (F)
items. High correlations MO with PF, UA with DA, AD
with F; Moderate correlations SC with DA, Low
correlations MO with F, UA with F, AD with PF; No
correlation SC and F; See Table 4 in original document
for exact correlations
Hazell et al. (2003)32 Construct—Known groups comparison of likely OAD
and not likely OAD using independent samples t-test.
EQ-5D index, VAS, MO, SC, UA, PD, AD significantly
different (po0.01)
Savoia et al. (2006)33 Construct—Known groups comparisons using odds ratio
adjusted for age and gender. Asthma and COPD groups
were more likely to report problems than those
without (po0.05). No significant difference found in
either group for % problems in any dimensions
A. Simon Pickard et al.524EQ-5D has gained widespread use for several reasons. It is
a brief, simple measure for patients to understand and to
complete, imposing minimal respondent burden. The mea-
sure is easy to score and interpret. A single summary score is
generated by applying societal preference weights to a
health state classifier completed by the patient. The self-
classifier consists of five dimensions (mobility, self-care,
usual activities, pain/discomfort, and anxiety/depression),
each with three levels of response (no problems, some
problems, or extreme problems). The utility score is
typically interpreted along a continuum where 1 represents
best possible health and 0 represents dead, with some
health states considered worse than dead (o0). In addition
to the self-classifier, the EQ-5D contains a 20 cm visual
analog scale (VAS) ranging from 0 (worst imaginable health)
to 100 (best imaginable health) along which the respondent
rates their health today. The index-based utility scores can
be used compare burden of disease across different
conditions and facilitate the calculation of quality adjustedlife years (QALYs) that are incorporated into economic
evaluations of health care interventions.9
The ability to convert self-classifier responses into a
single preference-based score makes the EQ-5D practical for
clinical and economic evaluation.10 Perhaps the most
popular set of preference weights are based on the United
Kingdom population,11 but many other country-specific
algorithms are available.10 National catalogs of EQ-5D scores
for chronic conditions have been published to facilitate
insight into the overall impact of disease and inform health
care resource decision-making.12 Evidence from the litera-
ture on the use of the EQ-5D in different conditions, such
chronic respiratory illnesses, can help to inform the
appropriate use and limitations of its application as well
as understand patient-reported health at different stages of
the illness. Thus, the purpose of this paper was twofold. The
first objective was to synthesize the evidence of validity and
reliability of the EQ-5D in studies of asthma and COPD. The
second objective was to summarize the EQ-5D-based scores
A
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Table 3 EQ-5D Index-based and VAS scores.
First author, year,
reference: group
N Index mean
(SD) Median
(IQR)
VAS mean
(SD) Median
(IQR)
% Patients reporting problems in each dimension Scoring algorithm Author and reviewer
comments
MO SC UA PD AD
Asthma
Burstrom (2001)19
Asthma patients,
Swedish population
253 0.80 (0.02) 80 (19) 2/3- 21 2/3- 3 2/3- 14 2/3- 59 2/3- 32 United Kingdom11
Garratt (2000)20
Non-smoker 177 0.80 (0.27) United Kingdom11
Smoker 36 0.76 (0.25)
Greiner (1999)35
Level 1 asthma 40 0.89 (0.16) 82 (14) N/R
Level 2 asthma 42 0.73 (0.25) 65 (18)
Level 3 (serious
asthma)
36 0.42 (0.30) 45 (15)
Lubetkin (2005)21
Asthma 74 (1) United Kingdom11 EQ-5D Index MEPS
study results are
reported in Sullivan
paper for Asthma
and COPD
Meszaros (2006)36
Asthma patients, 0.91
Age 20
Age 30 0.82
Age 40 0.76
Age 50 0.70
Age 60 0.65
Age 70 0.53
Oga (2003)22
Initial assessment
(asthma)
54 0.81 (0.19) 1- 83 1- 96 1- 70 1- 54 1- 65 Japan18
2- 17 2- 4 2- 28 2- 37 2- 30
3- 0 3- 0 3- 2 3- 9 3- 6
3 months post initial
assessment (asthma)
54 0.89 (0.15) 1- 91 1- 94 1- 85 1- 74 1- 78
2- 9 2- 6 2- 15 2- 26 2- 22
3- 0 3- 0 3- 0 3- 0 3- 0
6 months post initial
assessment (asthma)
54 0.88 (0.15) 1- 94 1- 96 1- 91 1- 70 1- 76
2- 6 2- 4 2- 9 2- 30 2- 22
3- 0 3- 0 3- 0 3- 0 3- 2
Szende (2004)23
Poor control 46 0.52 48 United Kingdom11 Substantial HRQL
differences were
detected between
different asthma
control levels.
Proportion of
problems on each
dimension was
reported by asthma
control level
Moderately reduced
control
82 0.65 59
Mildly reduced
control
64 0.76 67
Good control 36 0.93 76
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Table 3 (continued )
First author, year,
reference: group
N Index mean
(SD) Median
(IQR)
VAS mean
(SD) Median
(IQR)
% Patients reporting problems in each dimension Scoring algorithm Author and reviewer
comments
MO SC UA PD AD
Wasserfallen
(1999)24
Allergic Rhinitis
patients, most
severe MAQOL score
20 72 Reported the EQ-5D
VAS on a scale from 1
to 10
Allergic Rhinitis
patients, least
severe MAQOL score
20 84
Sullivan (2005)37
Asthma 1723 0.802 United States17
0.77
[0.77–
0.83]
COPD
Harper (1997)27
Initial assessment 42 0.52 (0.16) N/R
53.1
49 51 (16)
Hazell (2003)32
Likely obstructive
airways disease
1054 0.63 63 2/3- 47 2/3- 20 2/3- 49 2/3- 63 2/3- 54 United Kingdom11 OAD determined by
patient-reported
symptoms, and could
be either asthma or
COPD
Punekar (2007)38
Primary care
physician
(PCP)treated-GOLD I
patients
92 0.77 (0.20) United Kingdom11 Paper also stratifies
EQ-5D results by sex,
age, number of
exacerbations, MRC
dyspnea, and
symptoms
PCP-GOLD II 77 0.68 (0.27)
PCP-GOLD III 79 0.62 (0.27)
Respiratory
specialist treated-
GOLD I patients
93 0.68 (0.20)
RS-GOLD II 314 0.72 (0.27)
RS-GOLD III 340 0.64 (0.28)
USA-PCP 374 2/3- 60 2/3- 19 2/3- 52 2/3- 47 2/3- 44
USA-RS 375 2/3- 68 2/3- 29 2/3- 62 2/3- 40 2/3- 39
UK-PCP 98 2/3- 64 2/3- 27 2/3- 57 2/3- 58 2/3- 46
UK-RS 64 2/3- 77 2/3- 27 2/3- 66 2/3- 45 2/3- 42
Spain-PCP 265 2/3- 49 2/3- 28 2/3- 42 2/3- 52 2/3- 37
Spain-PS 275 2/3- 52 2/3- 36 2/3- 49 2/3- 40 2/3- 37
Rutten-Van Molken
(2006)28
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GOLD II 622 0.79 (0.19) 68 (16) United Kingdom11 Study also reports %
patients reporting
problems by
dimension. The % of
patients reporting
problems increased
with COPD severity
in MO, SC, UA
GOLD III 513 0.75 (0.21) 62 (17)
GOLD IV 91 0.65 (0.23) 58 (16)
GOLD II 622 0.83 (0.14) United States17
GOLD III 513 0.80 (0.15)
GOLD IV 91 0.73 (0.15)
See original paper
for stratification by
number of
comorbidities
Savoia (2006)33 United Kingdom11 COPD strongly
associated with
mobility
impairment. Asthma
and COPD mainly
affected the UA
domain. The % of
people with asthma
or COPD was
reported by the
primary care
physician
Stahl (2005)29
GOLD I 26 0.84 (0.15) 73 (21) United Kingdom11 Scores were also
stratified by BTS-
based stage
GOLD II 91 0.73 (0.23) 65 (24)
GOLD III 33 0.74 (0.25) 62 (21)
GOLD IV 9 0.52 (0.26) 37 (28)
Stavem (1999)30
All (COPD) 59 0.73 United Kingdom11
[0.62–
0.81]
Sullivan (2005)37
COPD 1609 0.797; 0.77 United States17
[0.76–
0.83]
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A. Simon Pickard et al.528reported in studies of asthma and COPD, and to estimate
mean utility scores according to stage of disease where
possible.
Methods
Data collection and assessment
A computerized search of the published literature was
performed using MEDLINE and EMBASE for January 1, 1988 to
January 31, 2007. The search strategy combined exploded
EMBASE subject headings and keywords relating to asthma or
COPD and EQ-5D in two separate searches. EMBASE terms for
asthma were: (asthma/exp) AND (‘eq 5d’ OR euroqol OR
‘eq5d’). The EMBASE search for COPD was: (‘chronic
obstructive lung disease’/exp) AND (‘eq 5d’ OR euroqol OR
‘eq5d’). The search in MEDLINE was identical, except for the
replacement of medical subject headings for exploded
terms. The Euroqol website (www.euroqol.org) was also
used to identify unique references that may not have been
captured in the initial literature search. In addition, author
libraries were hand searched.
Upon identification of the potential body of literature,
two independent reviewers screened citations/abstracts for
potential relevance to the two objectives (CTW, EJ). UponLe
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Figure 2 EQ-5D index mean/initial screening, full papers were retrieved. All original
research articles were included if the investigation reported
EQ5D scores and/or psychometric properties for patients
with chronic respiratory disease, i.e. asthma or COPD. One
investigator (ASP) screened all of the articles for inclusion,
with any concerns resolved by consensus. When several
articles reported results from the same dataset, EQ-5D
scores were reported from only one article to avoid double
counting. Due to limited fluency in other languages, only
utility scores were abstracted from papers in languages
other than English and Spanish. No other restrictions were
applied.13 Each article was abstracted using a piloted and
revised abstraction form developed by the investigators that
followed standardized criteria.14 Results were checked for
accuracy by an alternate investigator during computer entry
(SP, CTW, EJ). Any issues regarding abstraction were
resolved through consensus.
Data analysis
Psychometric properties were summarized based on type of
property assessed (validity/reliability/responsiveness), the
comparison performed, and the statistical test result.
Papers that grouped asthma and COPD patients together
when reporting psychometric properties were included in50
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EQ-5D use in COPD and asthma 529the COPD section for convenience. The term content validity
was used to describe comparisons of patient groups or
disease characteristics; construct validity referred to
analysis comparing the relationship between EQ-5D and
other measures.15
Scores that were not reported using the appropriate range
of scale were transformed, i.e. index-based scores anchored
by 0 and 1, VAS scores range from 0 to 100. EQ-5D scores
were described by stage of disease if reported in the results
section of a study. A spirometry-based measure of disease
severity has been established for COPD by the global
obstructive lung disease initiative, i.e. GOLD stage, where
higher stage represents more severe symptoms of COPD.3
For asthma, guidelines for reporting severity of asthma
have been proposed by the global initiative for asthma
(GINA).2 Otherwise, results were reported as overall
scores if reported, or stratified by risk factor (i.e. smokers
vs. non-smokers), or by demographic factors (e.g. by sex,
age). Standard deviations were calculated from 95%
confidence intervals or standard errors when they were
not directly reported. In Figures 3–6, error bars represent
95% confidence intervals (calculated from reported SD)
about the mean or show the inter-quartile range about the
median.0.40
0.50
G
O
LD
 IV
 [2
9]
G
O
LD
 IV
 (U
K
 A
lg
or
ith
m
) [
28
]
G
O
LD
 IV
 (U
S
 A
lg
or
ith
m
) [
28
]
P
C
P
- G
O
LD
III
 [3
8]
R
S
- G
O
LD
III
 [2
8]
G
O
LD
 II
I [
29
]
G
O
LD
 II
I (
U
K
 A
lg
or
ith
m
) [
28
]
G
O
LD
 II
I (
U
S
 A
lg
or
ith
m
) [
28
]
P
C
P
-G
O
LD
 II
 [3
8]
R
S
- G
O
LD
 II
 [3
8
G
O
G
O
LD
I
E
Q
-5
D
 I
n
d
e
x
Stratified by Severity
1.00
0.90
0.80
0.70
0.60
0.30
0.20
0.10
0.00
• -Mean (95% CI);     -Median (IQR)
Figure 3 EQ-5D index mean/mA meta-analytic approach to the estimation of mean
utility scores according to stage of COPD was employed by
calculating pooled means. Sufficient studies were available
that reported UK utility-based scores and COPD severity
based on GOLD stage. Insufficient information on disease
stage, e.g. GINA level, was available for studies in asthma.
Random-effects based pooled means for index-based scores
were calculated using the DerSimonian and Laird method,
which simplifies to the inverse variance fixed effects pooled
means method when studies are sufficiently homogenous.16
For each GOLD stage, an inverse variance fixed effects
pooled mean and tau (t) statistic of heterogeneity was
calculated to determine whether fixed or random effects
was the appropriate method of pooling. When t is negative,
there is no need for adjustment for random effects, and the
inverse variance fixed effects pooled mean and standard
error are appropriate. Calculations were performed using
Microsoft Office Excel version 2003.Results
The electronic search of databases on January 19, 2007
resulted in the identification of 16 asthma studies and 12]
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A. Simon Pickard et al.530papers for COPD, 1 of which overlapped (Figure 1). An
additional five unique articles were identified in the Euroqol
database (2 asthma, 1 COPD, 2 both), with one article
included from personal libraries for a total of 32 articles. Of
the 32 articles, 18 papers met the selection criteria, 16 of
which reported an EQ-5D index score, VAS score, and/or
provided responses to the self-classifier system. Fifteen
papers presented evidence of the psychometric properties
of the EQ-5D.
Of studies reporting mode of administration (n ¼ 13), 31%
were filled out on-site by respondents, 46% were mailed-out
questionnaires, and 23% were administered through tele-
phone interview. Prospective studies were more common
than retrospective (75% vs 25%) and the majority of studies
were cross-sectional (63%). Most studies (77%) reported EQ-
5D index scores using the UK-based algorithm,11 although
scores based on United States17 and Japanese18 preferences
were also used. However, five studies (31%) did not explicitly
state which algorithm was used to calculate index-based
utility scores. It was possible to determine the algorithm
used from the references cited for two of these studies.
Study populations varied with respect to stage of asthma or
COPD, age distribution, and focus of study (Table 1).
Most studies of asthma and COPD patients that reported
psychometric properties of the EQ-5D investigated construct
and/or convergent validity of the EQ-5D. Most studies0
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Figure 4 Visual analog scale mreported correlations with other HRQL measures or clinical
indicators of asthma/COPD (Table 2).19–34 To support con-
vergent validity, EQ-5D results were examined on the basis of
strength of correlation with disease-specific or generic
measures of HRQL, including the AQLQ, NASQ, SF-12, SF-36,
SF-6D, St. George’s Respiratory Questionnaire, Rhinoconjucti-
vitis Quality of Life Questionnaire, MAQOL, Karnofsky scale,
and 15-D. EQ-5D index and VAS scores were also correlated
with clinical measures such as FEV1, asthma symptom and
bother scores, breathlessness, the 6min walking test, number
of emergency room visits, number of hospital admissions,
dyspnea, and GOLD stage of disease severity.
Studies of asthma reported index scores that ranged from
a mean of 0.42 (SD 0.30) to 0.93 (no SD reported) (Table 3,
Figure 3). VAS scores ranged from a mean of 45 (SD 15) to 84 (no
SD reported) (Table 3, Figure 5).19–24,35–37 The poorest (lowest)
VAS scores and index-based scores were reported in serious
asthma,35 poor control of asthma,23 and older patients.36
Studies of COPD reported EQ-5D index scores ranging from
0.52 (SD 0.16) to 0.84 (SD 0.15) (Table 3, Figure 4). VAS
scores in COPD studies ranged from 37 (SD 28) to 73 (SD 21)
(Table 3, Figure 6).27–30,32,33,37,38 It was more common for
COPD studies than asthma studies to stratify patients by
disease severity. In almost all studies, mean utility scores
declined as disease severity got worse. The lowest EQ-5D
index-based and VAS scores were associated with GOLDllergic 
initis, 
ghest 
AQOL 
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EQ-5D use in COPD and asthma 531stage IV29 and the baseline scores in a study of multiple
measures given to patients attending routine COPD clinics27
(Figures 2–5).
In COPD, EQ-5D index-based scores stratified by GOLD
stage were sufficiently homogenous (t2o0) such that the
inverse variance method of calculating the fixed effect
pooled means could be used. Pooled mean index-based
utilities scored using the UK-based algorithm decreased with
the severity of GOLD stage: stage I ¼ 0.74 (0.68–0.84), stage
II ¼ 0.74 (0.68–0.79), stage III ¼ 0.69 (0.62–0.75) and stage
IV ¼ 0.61 (0.52–0.65) (most severe).
In examining the dimension-specific burden of disease among
asthma studies, problems with pain/discomfort tended to be
most common, followed by problems with anxiety/depression.
Studies of COPD generally had a higher proportion of patients
reporting problems as compared to asthma studies across
dimensions of the self-classifier (Table 3, Figures 6–10).
Of studies that reported EQ-5D index or VAS scores, 3 out
of 13 studies (23%) did not report standard deviations
(Figures 2–5). Almost 50% of studies raised the issue of
ceiling effects for the EQ-5D. Non-parametric statistics were
applied in 79% of studies when appropriate in comparing EQ-
5D scores because of non-normal distributions. Four of 14
studies (29%) reported median scores for the index and/or
VAS scores as a measure of central tendency. One study
reported (unweighted) means based on the ordinal level
responses to dimensions on the EQ-5D.0
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Figure 5 Visual analog scale mDiscussion
The trend towards greater use of patient-reported outcome
measures in studies of asthma and COPD using EQ-5D in recent
years is similar to the trend observed in the cancer litera-
ture.39 This is further affirmation that patient reported
outcomes such as health status and quality of life are gaining
acceptance as routine measures in clinical studies, particularly
in chronic conditions. This summary of EQ-5D index and VAS
scores in respiratory-related conditions complements a general
catalog of EQ-5D scores associated with diseases reported by
Sullivan et al.12 a review of quality of life estimates across
conditions by Tengs and Wallace,40 and pharmacoeconomic
evaluations of COPD by Ruchlin and Dasbach.41
Because many COPD studies reported EQ-5D summary
scores stratified by GOLD stage, calculation of pooled means
was possible. Lower utility scores were associated with more
severe stages of COLD but little difference could be
discerned between the milder stages of disease, i.e. GOLD
stages I and II. As GOLD stage is based on FEV1 levels, which
are only weakly correlated with EQ-5D utility scores,30 these
results were not surprising. A distinction in utility scores was
more clearly observed between the more severe stages of
COPD compared to the milder stages of disease. The limited
ability to distinguish between milder stages of disease may be
a limitation in the sensitivity/discriminative ability of EQ-5D.
It also raises the issue of whether there is a threshold level ofOLDII
29]
GOLD II
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GOLDI
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Figure 6 Distribution of responses to mobility dimension of EQ-5D.
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Figure 8 Distribution of responses to usual activities dimension of EQ-5D.
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Figure 10 Distribution of responses to anxiety/depression dimension of EQ-5D.
A. Simon Pickard et al.534clinical severity of COPD at which utilities are affected.
Heterogeneity in studies, particularly patient characteristics
such as comorbidities, can affect utility scores and repre-
sented a limitation of pooling scores across studies.
Pooled values may be useful as a benchmark for compar-
isons of burden of disease both within respiratory conditions
and among multiple disease states. In addition, pooled mean
utility scores summarized according to GOLD stages may be
useful to modeling of health outcomes in economic evalua-
tions of COPD. Alternatively, utility scores from a single, large
study with a well-defined patient cohort may be more suitable
depending on the goals of the evaluation.
Evaluations of the validity and reliability of EQ-5D
generally supported its use in asthma and COPD, although
there was some evidence of a ceiling effect in asthma,
which has also been noted in population health studies using
the EQ-5D.39 The simplicity of EQ-5D was supported in COPD,
as it was reported to be easily understood by COPD
patients.42 Methodologically, the ordering of the EQ-5D
within a series of measures (either generic or disease
specific) was not found to affect the response rate or time to
respond to the EQ-5D self-classifier or rating scale in a
sample of patients with asthma.43 It is important to note
that different algorithms can produce different EQ-5D
index-based scores, e.g. US vs UK,28 which can detract from
comparability of utility scores between studies.
Studies of asthma tended to report medians rather than
means for summary scores due to the skewed distribution of
scores and ceiling effects of EQ-5D among healthier asthma
patients. In comparison to the characteristics of asthma
patients, COPD patients were generally older and reportedmore problems across the dimensions of health than asthma
patients. Consequently, index-based scores among COPD
patients were less subject to potential ceiling effects and
the distribution of scores were less skewed, facilitating the
use of means as a measure of central tendency.
Conclusion
HRQL measures such as EQ-5D can assist clinicians to
understand the impact of respiratory disease on patients
and to better inform clinical decision-making and resource
allocation. Evidence of validity and reliability supports the
use of the EQ-5D in both asthma and COPD, although some
ceiling effects are evident in asthma. As would be expected,
asthma and COPD scores varied based on the severity of the
condition and characteristics of the study population.
Pooled means calculated according to GOLD stage asso-
ciated lower HRQL with more severe COPD. Pooled mean
estimates of EQ-5D preference-based scores according to
GOLD stage may be useful for modeling outcomes and
calculating quality-adjusted life-years in economic evalua-
tions of COPD.
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this manuscript.Appendix A. Abbreviations used in tables/
figuresAD anxiety/depression
ANCOVA multivariate analysis of covariance
AQLQ Asthma Quality of Life Questionnaire
BMI body mass index
BTS British thoracic society
COPD chronic obstructive pulmonary disease
DA daily activities
EQ-VAS EuroQol visual analog scale
ES effect size
F Feelings
FEV1 forced expiratory volume1
GOLD the global initiative for chronic obstructive lung
disease
ICC intraclass correlation coefficient
IQR inter quartile range
M/F male/female
MAQOL McMaster Asthma Quality of Life Questionnaire
MCS the mental component summary score
MEPS medical expenditure panel survey
MO mobility
MRC medical research council
NASQ Newcastle Asthma Symptoms Questionnaire
OAD obstructive airways disease
PCP primary care physicians
PCS the physical component summary score
PD pain/discomfort
PF physical functioning
RS respiratory specialists
SC self-care (personal care)
SD standard deviation
SF-12 short form-12
SGRQ St. George’s Respiratory Questionnaire
SRM standardized response mean
TTO the time trade off
UA usual activities
UK United Kingdom
US United States
VAS visual analog scaleReferences
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